Dexmedetomidine: a drop in metabolism that disappears after two days

Sedation studied over five days

Dexmedetomidine is an alpha-2 adrenergic receptor agonist. It induces sleep-like sedation and reduces overall metabolism. The researchers wanted to determine whether this reduction could be sustained for several days to decrease energy and oxygen needs, as well as carbon dioxide production.

Five healthy adults received the drug by subcutaneous infusion over several days in a laboratory, under a protocol planned to last five days. Five other participants received a placebo for one or five days. Gas exchange and energy expenditure were measured using intermittent indirect calorimetry.

An initial drop, not lasting energy savings

Compared with resting metabolism, the researchers report decreases in oxygen consumption, carbon dioxide production and energy expenditure. For energy expenditure, the estimated effect at the six-hour measurement point corresponds to −577 kcal per day, with a 95% confidence interval ranging from −1,016 to −137 kcal per day. Expressing this as a daily equivalent does not demonstrate sustained energy savings throughout the study.

Compared with placebo, the drug also caused mild sedation, a heart rate 15 beats per minute lower and a core body temperature 1.3 °C lower.

But the effects on physiological variables diminished over time and were no longer present after the second day. Yet peak and trough plasma concentrations of the drug did not change from day to day. The authors interpret these findings as the development of tolerance by the third day.

Limited feasibility, with effects after stopping

Participants reported rebound anxiety and insomnia after the study. The abstract specifies neither their frequency nor their severity. The initial drop in metabolism therefore cannot be presented as a benefit in isolation from its other effects.

This trial documents a temporary physiological response in a laboratory. It does not demonstrate improved survival chances in a rescue situation or the value of prolonged use. Rapid tolerance is precisely the main obstacle to the objective being studied.

What we can take away

Dexmedetomidine temporarily reduced metabolic needs in a few healthy adults, but the effect disappeared after two days. This finding does not validate a sustainable energy-saving strategy.